Ricerca Biosciences, a preclinical CRO, has partnered with Fulcrum Pharma, an Aptiv Solutions company and a provider of drug development consulting and regulatory services. The collaboration aims to help biopharmaceutical companies move a candidate from development to clinical evaluation more efficiently.
“Fulcrum Pharma brings experience in IND authorship and regulatory approval, which fits well with Ricerca’s preclinical services in discovery pharmacology, chemical development and drug safety assessment,” said Ian Lennox, CEO of Ricerca.
Ricerca Biosciences provides preclinical services from early discovery medicinal chemistry, compound screening, profiling and lead optimization through full drug safety, metabolism and efficacy development support, as well as clinical supply and commercial API production capability. Fulcrum Pharma provides strategic and operational regulatory support.